76541
document
Deleterious effects of low-dose oestrogen therapy on coronary status in patients with prostatic cancer . The effects of oestrogen therapy and of orchidectomy on coronary status , as reflected by exercise ECG-testing before and after one year of treatment , were assessed in a randomized study of patients ( N = 100 ) with prostatic cancer . Oestrogen was given as polyestradiol phosphate 80 mg i.m . per month in combination with 150 micrograms ethinylestradiol p.o . per day . There were no significant inter-group differences in conventional risk factors or in pre-treatment exercise test results . Twelve months after the start of therapy the oestrogen group showed a significantly greater depression of the ST-segment during maximal exercise in leads CH2 ( P less than 0.0005 ) and CH5 ( P less than 0.01 ) compared with the pre-treatment depression . Twenty-five per cent ( N = 13 ) of the patients in the oestrogen group suffered cardiovascular complications during the year of therapy , whereas no such complications were observed in the orchidectomy group . However , even the patients in the oestrogen group who had not suffered cardiovascular complications had significantly greater depressions of the ST-segment during exercise both in lead CH2 ( P less than 0.0005 ) and in CH5 ( P less than 0.05 ) . There was no significant change in the ST-segment level in the orchidectomy group twelve months after surgery . In summary , we found evidence of an induction of myocardial ischaemia during treatment with exogenous oestrogens at low dosage in patients with prostatic cancer . This deleterious effect of oestrogen on the coronary status argues against oestrogen therapy , since oestrogen has not been shown to be more beneficial than orchidectomy against prostatic carcinoma .
76542
Intervention_Pharmacological
low-dose oestrogen therapy
76543
Intervention_Pharmacological
oestrogen therapy
76544
Intervention_Surgical
orchidectomy
76545
Intervention_Pharmacological
Oestrogen
76546
Intervention_Pharmacological
polyestradiol phosphate
76547
Intervention_Pharmacological
150 micrograms ethinylestradiol
76548
Intervention_Pharmacological
exogenous oestrogens
76549
Intervention_Pharmacological
oestrogen
76550
Intervention_Pharmacological
oestrogen
76551
Outcome_Adverse-effects
cardiovascular complications
76552
Outcome_Adverse-effects
cardiovascular complications
76553
Outcome_Physical
depressions of the ST-segment
76554
Outcome_Physical
ST-segment level
76555
Outcome_Physical
myocardial ischaemia
76556
Participant_Condition
patients with prostatic cancer .
76557
Participant_Sample-size
N = 100
76558
Participant_Condition
prostatic cancer